Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2024-09-02 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 August 2024. It details movements in issued shares, treasury shares, share options, and confirms no changes in authorized share capital or other share-related agreements. The document is submitted to the Hong Kong Exchanges and Clearing Limited and is a regulatory monthly return concerning share capital and share movements. It is not a financial report, earnings release, or management discussion. It is a regulatory filing reporting share capital movements as required by the exchange rules. The document length is about 5722 characters, and it contains detailed share movement data, but it is not a report like an annual or interim report. Therefore, the best classification is Regulatory Filings (RNS), as it is a compliance document reporting share capital movements under exchange rules.
2024-09-02 English
INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2024
Notice of Dividend Amount Classification · 100% confidence The document is titled 'INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2024' and provides detailed information about the dividend amount, payment dates, currency options, record dates, and share registrar details. It is an announcement specifically about the dividend amount and related shareholder information. The document length is 3703 characters, which is relatively short and focused solely on dividend details. There is no financial statement or comprehensive report content. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2024-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024' and contains detailed unaudited condensed consolidated interim financial statements including profit or loss, comprehensive income, financial position, and notes. It references compliance with HKAS 34 'Interim financial reporting' and includes comparative figures for the previous period. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure clearly identify it as an Interim / Quarterly Report covering a six-month period, with substantive financial data and analysis. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2024
2024-08-29 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It is a detailed announcement about the company's board structure and governance-related information. There is no financial data, no mention of a report publication, or voting results. The content fits the description of Board/Management Information (MANG), which covers announcements of changes or details about the company's board of directors or senior management. The document is relatively short and focused solely on board composition and committee roles, confirming it is not an Annual Report or Governance Information report but a Board/Management Information announcement.
2024-08-29 English
RESIGNATION OF NON-EXECUTIVE DIRECTOR&#x3b; RESIGNATION OF CHIEF EXECUTIVE OFFICER&#x3b; AND CHANGE OF CHAIRMAN OF THE BOARD, CHAIRMAN OF THE NOMINATION COMMITTEE AND MEMBERS OF THE CORPORATE GOVERNAN
Board/Management Information Classification · 100% confidence The document is an announcement from a company listed on the Hong Kong Stock Exchange regarding changes in its board and senior management positions. It details the resignation of a non-executive director and chairman, the appointment of a new chairman who is also resigning as CEO, and changes in committee memberships. The content focuses on personnel changes at the board and executive level, with no financial data, earnings, or report attachments. The document explicitly discusses board and management changes, which aligns with the category for announcements about changes in the company's board of directors or senior management. Therefore, the appropriate classification is 'Board/Management Information (MANG)'. The document length and detail support a high confidence in this classification.
2024-08-29 English
ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR SANJIU FOR THE SIX MONTHS ENDED 30 JUNE 2024
Earnings Release Classification · 95% confidence The document is an announcement from China Resources Pharmaceutical Group Limited regarding the unaudited interim financial results of its subsidiary CR Sanjiu for the six months ended 30 June 2024. It explicitly states that the financial results are unaudited and that the full interim report is published on the Shenzhen Stock Exchange website. The document provides key financial data but is relatively short (3819 characters) and serves as a summary announcement rather than the full interim report itself. According to the 'Menu vs Meal' rule, such announcements that summarize or highlight financial results without containing the full financial statements or detailed analysis should be classified as Earnings Release (ER). H1 2024
2024-08-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.